HDL as Therapeutic Tools

    January 2019 in “Springer eBooks
    Kyung-Hyun Cho
    Image of study
    TLDR Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.
    The document from 2019 explores the use of reconstituted high-density lipoprotein (rHDL) as a vehicle for drug and gene delivery, focusing on its potential to improve therapeutic outcomes and reduce side effects. The study found that rHDL containing the V156K variant of apoA-I, a protein component of HDL, enhanced the stability and delivery efficiency of adenoviral vectors for gene delivery and increased the solubility of poorly water-soluble drugs like rapamycin and minoxidil. Specifically, V156K-rapa-rHDL showed enhanced antioxidant ability and anti-senescence effects, with a 29% inhibition of CETP at 10 µM rapamycin and reduced cellular senescence in human dermal fibroblast cells. For hair loss treatment, rHDL was used to solubilize minoxidil, resulting in a fivefold increase in solubility, improved antioxidant activity, and enhanced cell growth and tissue regeneration, with the V156K-minoxidil-rHDL variant showing the strongest effects. The study, which included experiments performed in duplicate and three independent experiments with seven subjects each, suggests that rHDL could be an efficient delivery system for drugs and genes, with the V156K mutation offering additional benefits.
    View this study on link.springer.com →

    Cited in this study